Ladies and gentlemen, thank you for standing by. Welcome, and thank you for joining QIAGEN's Conference to discuss the Third Quarter 2017 Results. At this time, all participants are in listen-only mode. Please be advised that this call is being recorded at QIAGEN's request and will be available on their website. The presentation will be followed by a question-and-answer session. At this time, I would like to introduce your host, John Gilardi, Vice President of Corporate Communications and Investor Relations at QIAGEN. Please go ahead, sir.

Thank you very much, and we appreciate you all taking the time to join us today for this conference call. Our speakers today are Peer Schatz, the Chief Executive Officer of QIAGEN; and Roland Sackers, the Chief Financial Officer. Also joining us today is Dr. Sarah Fakih from our IR team. On slide 2, you'll see the Safe Harbor statement explaining that the discussions and responses to your questions on this call reflect management's views as of today, Tuesday, November 7, 2017. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future and these constitute forward-looking statements for the purpose of the Safe Harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. QIAGEN disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the U.S. Securities and Exchange Commission. We will also be referring to certain financial measures not prepared in accordance with Generally Accepted Accounting Principles. You can find a reconciliation of these figures to GAAP in the press release and the presentation for this call, that is on our website. With that, I'd like to now hand over to Peer.

Well, thank you, John, and I would like to welcome all of you to this conference call. We are pleased with the solid performance for the third quarter of 2017. This is further confirmation of our confidence in achieving the full year goals for market share gains, adjusted net sales growth, and a double-digit increase in adjusted earnings per share. Our teams executed very well to deliver these results. We are determined more than ever to capitalize on the performance to-date in 2017 and create greater value from our Sample to Insight portfolio for molecular testing. I have these key messages for you today. First, the results for the third quarter were in line with our targets. Adjusted net sales rose 7% at constant exchange rates and this was in line with our outlook for about 7% CER growth. Adjusted earnings were $0.32 per share at constant exchange rates and also in line with the outlook for about $0.32 to $0.33, excluding the restructuring charge, which was less than $0.01 for the quarter. Second, our Sample to Insight portfolio is building momentum. Among the highlights in the third quarter was the QuantiFERON-TB test continuing to grow above the 25% CER target we have set for the year. Our teams also recently launched the fourth generation of this test in the United States and we are pleased with our contributions towards global TB control. The trends are also very positive for the QIAsymphony automation system. We are set to soon achieve the 2,000 placement and continue to see ongoing solid growth in related consumables. We will have more information for you on this topic at the upcoming in Association for Molecular Pathology meeting. As another highlight, we have reached an important milestone with more than 25 master collaboration agreements now in…

Thank you, Peer. Good afternoon to those of you in Europe and good morning to those of you in the U.S. I will review our financial performance for the third quarter of 2017 and later provide you with more details and our outlook for the fourth quarter and the update for the full year. As you saw in the press release, QIAGEN delivered another solid performance in the third quarter and we achieved our targets. Adjusted net sales was 8% to $364.4 million, and they were up 7% at constant exchange rates. The weakening of the U.S. dollar during the third quarter especially against the euro, led to the favorable currency impact. The adjusted net sales includes a full sales contribution from the OmicSoft acquisition and this represents about 1 percentage point of CER sales growth while about 6 percentage points came from the rest of the business. Moving down the income statement, the adjusted gross margin was 70.9% of sales and was down about 50 basis points from 71.4% in the third quarter of 2016. The modest decline included the adverse impact of the double-digit CER increase in revenues from pharma master collaboration agreement. These revenues come with a gross margin usually in the 30% to 50% range, but provide benefits which drops to adjusted EBIT. Adjusted operating income was $97.9 million before the pre-tax restructuring charge, which represents an 11% increase from $88.1 million in the third quarter of 2016. As a result, the adjusted operating income margin rose to 26.9% of sales compared to 26% of sales in the year ago period. Sales development expenses remained steady at 10.6% of sales compared to the same period of 2016. For the first nine months of 2017, R&D expenses were lower compared to the third year (sic) [third quarter]…

Yeah, thank you, Roland. And I'm on slide 10 now to update you on key developments in our Sample to Insight portfolio during the third quarter. I'd like to walk you through specific progress on QuantiFERON-TB, our next-generation sequencing offering and personalized healthcare over the next few slides. But first, I'll touch briefly on QIAsymphony and Differentiated Technologies, both of which are continuing to show very solid growth. QIAsymphony is a remarkable success story. New placements were strong again during the third quarter and we are set to soon achieve the 2,000s cumulative placement, which we have set as a target for the end of this year. The system is adding value with an expanding menu of test content and also for front-end use for any downstream molecular testing, in particular, for NGS workflows. Our broad portfolio of Differentiated Technologies providing innovative solutions in large and cutting edge areas, such as Life Science Research include also the microbiome, single cell, and liquid biopsies and these continue to create great excitement, brand value, and drive growth. Our workflows for forensics are industry-leading and we were certified recently as meeting state-of-the-art ISO standards for purity and quality, which are absolutely critical in these products. Liquid biopsies are disseminating rapidly, as our solutions progress from research into the clinical arena. In the third quarter, the latest advance was a partnership with Clinical Genomics, a private company integrating our PAXgene, blood sample solution for collection and processing of cell free circulating DNA into their novel assay for recurrence testing in colorectal cancer. And now, let me review the progress on those first three growth drivers in further detail. I'm now on slide 11 to review key developments for QuantiFERON-TB, the world's leading blood test for providing highest accuracy and sensitivity in the detection of…

Thank you, Peer. I would like to review our outlook for 2017 starting with adjusted net sales growth of about 7% CER. This excludes the 2016 and 2017 revenues related to our decision to streamline the China portfolio as part of the new initiative. This outlook continues to include about 5 to 6 percentage points of organic growth and about 1 to 2 percentage points from acquisitions. As we discussed in the call for the second quarter results, the contributions from acquisitions is in the middle between 1 and 2 percentage points and could round up or down. A reconciliation can be found in the appendix to this presentation. In terms of adjusted earnings, we continue to expect about $1.25 to $1.27 per share. This is at constant exchange rates and excluding the restructuring charge, which is expected to be about $0.07 on a full year basis. The results for 2017 show a significant increase compared with the underlying $1.11 per share in 2016. As for currencies, based on rates as of November 3, we now expect a negative impact of about 1 percentage point on full year CER sales growth for movements against U.S. dollar, and a negative impact of about $0.01 on a full year adjusted EPS at CER rates. I would like to now provide some detailed information on our outlook for the fourth quarter and also the assumption for the full year. For the fourth quarter, our outlook for adjusted net sales is for growth of about 5% to 6% CER. This is also adjusted for the changes in the China business. This guidance is based on approximately 4 to 5 percentage point of organic growth against the strong Q4 2016, and includes about 2 percentage points of U.S. HPV headwinds. This also includes about 1 percentage points from the OmicSoft acquisition. Our outlook for adjusted diluted EPS in the fourth quarter of 2017 is for about $0.41 to $0.42 per share at constant exchange rates, and this excludes an anticipated $0.01 of after-tax restructuring charges for the efficiency initiatives. The adjusted tax rate assumption for the fourth quarter is for 16% to 17%, and about 234 million shares outstanding. In terms of expected currency movements against U.S. dollar for the fourth quarter, and based on rates as of November 3, 2017, we expect a tailwind of about 2 percentage points on adjusted net sales and a neutral impact on adjusted diluted EPS. With that, I would like to hand back to Peer.

Yeah. Thank you, Roland. I would now like to provide a quick summary before we move into Q&A. And let me review what we have announced. First, we achieved our targets for the third quarter of 2017 with adjusted net sales growth of 7% CER and adjusted earnings of $0.32 per share. Second, our Sample to Insight portfolio continues to build momentum. Among the highlights was the ongoing growth of the QuantiFERON latent TB test, along with double-digit CER gains in companion diagnostics in QIAsymphony related consumables. And third, we are on track to deliver market share gains, solid adjusted net sales growth, and a double-digit increase in adjusted earnings per share for 2017. This gives us renewed confidence in our growth phase to excel towards 2020. And with that, I'd like to hand back to John and the operator for the Q&A session. Thank you.

Ladies and gentlemen, at this time we'll begin the question-and-answer session. First question comes from the line of Steve Beuchaw with Morgan Stanley. Please go ahead. Steve C. Beuchaw - Morgan Stanley & Co. LLC: Hi. Good morning, and thanks for the time here. I'd ask just one with a little bit of detail in it. I thought it'd be interesting given that we're here at – almost at the one year anniversary of the introduction of your Long Range Plan to investors in November of last year. If you could just tell us – what do you think are the two or three things that you've learned this year that are the most important, that help you to refine your thinking on the long-term plan and how you think that evolves over the next two or three years? And then, within that, it'd be helpful if you could give us just a couple of details on things that emerged here. The instrument number was a little stronger, should we think about instruments being a little bit better from here? And then on HPV post the fourth quarter, how we're thinking on HPV going forward? Thanks so much.

Sure. Well, first question, Steve. Thanks for that. The Long Range Plan, we're progressing very well on it. As you know, it is something that the management team is also incentivized against and we are moving very well ahead on that path. The best thing about having a Long Range Plan, it builds confidence to an organization and also allows – creates stability and at the same time, agility. And clearly, we are able to address opportunities that emerge in a very swift way and this is also something we've been seeing over the course of the year. So, the long-term plan is fully intact and we are executing towards it. The instrumentation changes come from the fact that we highlighted this – I think it was in the first quarter conference call, that we were not satisfied with how we were managing the pipeline in terms of instrumentation. We significantly revamped that. What you are starting to see is some of the benefits there. The growth that we saw in the third quarter is not good enough. We think we have more potential also beyond that, and we are working hard to get there. In terms of the HPV portfolio, this is in the meantime a very small percentage of our sales but obviously very volatile. The majority of the sales are now also big tender related and related to several larger partnerships. And I think what you saw now in the third quarter was a very proactive move to change the way we're approaching the Chinese market, which is the second largest market for us in the world, and restructure the way we are selling this product by contributing into a distributor aggregator that can create a broader portfolio and a more focused and more targeted approach towards the women's health markets while we can focus on the tuberculosis and the pathology markets and the fascinating opportunities of the MAQGEN joint venture that we're very pleased with that is lifting off as we speak. So this is going to become – HPV is definitely a much smaller percentage of our revenue base now going forward.

The next question comes from the line of Tycho Peterson of JPMorgan. Please go ahead.

Hey, thanks. I want to focus on the fourth quarter guide here. I understand you maintained the organic growth guide by removing the China business, but you did reduce on an apples-to-apples basis compared to the last quarter guide. So, couple of things to just ask on here. Why is this the case when you're selling off slower-growing assets? Why did the divested and discontinued businesses have such an outsized impact when as you say they're only 1% to 2% of revenues? And then HPV, it's a small piece of the business as you just highlighted, so how is it a 2% headwind when it's only 5% of revenues or so in the fourth quarter? Thanks.

Thanks, Tycho. Yeah, I'll hand off to Roland, but first to note the – when I said that HPV is a smaller percentage of our sales, I said going forward, because now the Chinese, the second largest market is now substantially reduced in terms of its exposure to QIAGEN. And so, from that perspective, I was talking going forward. But Roland, do you want to take the other questions?

Yeah. Hi, Tycho. I think you really have to take it by the pieces here. And first of all, I think if you look into China, what Peer has just also presented around strategic opportunities we see is that, first of all, again, you have to recall that we clearly discontinued certain PCR-related products, and of course, if we would have produced in the fourth quarter, we would have met our guidance with or without that. So, I think just now only fair to say that again, as the producers are not produced but again, if we wouldn't have stopped it, we would have met our guidance. But of course, we do need this capacity to bring new products into China where we believe mid-term we get even not only a better growth but even more important, better profitability contribution from, and I think that is expect – what you are expecting from management to do this kind of business related decision. On the HPV side, I think the reason why we're excluding them, we're in the middle of setting up the structures as Peer said before. It's not fully clear yet, therefore we more or less, for the time being, exclude that from our guidance. If it will end into for example, a joint venture, we will end in the distribution, it will end in the partnership, which of course all has very different revenue or conditions related to accounting consequences. And I think it's hard for us right now to guide for that, so I would say that it's a right way also to take that out. And so again, I only can say what we said before, for us, it is clear consequences of driving efficiency all over the world, and then taking the opportunities. And if it requires for ramping up some other stuff to stop certain things, which don't deliver the, I would say, needed profitability, then it's also for the (39:11) right consequences.

The next question comes from the line of Daniel Wendorff of Commerzbank. Please go ahead sir.

And thanks for taking my questions. My key question would be – and Peer, you mentioned that your NGS workflow is placing pretty well also on a fully integrated basis. My question there would be, can you potentially tell us, I guess an indication what the level of payment or reimbursement? And if you would receive the test results just that, yeah, the certain feeling (39:50) here? And second follow-up question would be on your pharma and customer growth in the third quarter. This has been pretty good, actually, I thought over the last few quarters, even though you cautioned the market a bit that, it can be good in one quarter and not so good in the next quarter. So, currently we haven't really seen this. Is the 5% a good indication going forward now as well? Thank you.

Yeah, thanks, Daniel. So I'll talk about the second one first. The pharma markets are indeed quite attractive and I'd say we're doing okay in the pharma markets. I see more potential there and we are discussing opportunities to further increase our presence and also our penetration into that market. The pharmaceutical industry has dramatically changed the way they're purchasing over the last 10 years and these are things that provide opportunities for companies like ours. Some – many pharma companies are moving away from feet on the ground approaches to more digital integration approaches and that provides a lot of benefits for us, as we have a – in the meantime quite leading position in the digital commercialization arena. Number two is, in terms of the GeneReader, the majority of the placements are in the clinical benchtop oncology sequencing area and we have several customers already up and running, and full throughputs. And remember, we have up to summer only had really one panel that we had fully validated and we're promoting just to control also the comparisons, make sure they're apples-to-apples. We have several customers running north of a 150,000 in terms of consumable throughput on the system, and we have others in later stage of validation. And on top of that, we – as we talked about in our last conference call, we're expanding the menu significantly with quite a unique new lung panel and with further other hereditary cancer panels. And the uptake is quite good. And if you just look at the region where you come from Daniel is, this is a region where we have a – quite a dominant market share in terms of cancer panel testing. And we are starting to see a lot of regions further adopting this high throughput cancer panel testing approach on the GeneReader very successfully.

Your next question comes from the line of Brian Weinstein of William Blair. Please go ahead. Brian D. Weinstein - William Blair & Co. LLC: Hey, guys. A question for you on companion diagnostics. I mean, you talked a lot about it and you have a lot of master agreements and whatnot, but can you – is there any way to really help us dial-in on what's really important for 2018? How should we measure the progress there, specifically, any of the collaborations that you think are more important than others or in terms of opportunity to drive revenue next year, or will be more high-profile than others? Thanks.

Sure, Brian. Excellent question and there – the market really changed. I'd say in the first few years of companion diagnostics, it was very late-stage products and the opportunity to create a diagnostic test and generate revenues from it was quite high. And we have a substantial double-digit million dollar number from tests like that that are being used around the world very successfully. And including also a handful of FDA approvals in the United States and this business remains very attractive. And there was a period where we saw a lot of pharma companies go very early into the pipeline and then with higher risk associated with it and we saw quite a bit of attrition between the years 2013 and 2016, let's say, but ever since about 12, 18 months ago and this is also partly due to a very deliberate focus of the team. We have created a very nice balance between a very long term super exciting projects and near-term revenue opportunities. And one thing I'm most proud about is that we are actually looking at a whole series of new product launches potentially in 2018 if the drug makes it over the finish line. And that obviously is what we're really after is the kits sales. So it's nice to have the development revenues, but what we're really after is a recurring kits sale and the most exciting ones this year, no question is the – are the companion diagnostic deals around immuno-oncology, and they're really piling up. It's a great opportunity for us and a perfect fit for GeneReader.

Your next question comes from the line of Scott Bardo with Berenberg. Please go ahead. Scott J. Bardo - Joh. Berenberg, Gossler & Co. KG (United Kingdom): Yeah. Thanks very much for taking my question. First question just relates to GeneReader. I think it's quite difficult to track progress of GeneReader apart from some qualitative comments. So just wondered if you could talk a little bit about how the instruments are placing as compared to last year and perhaps share a little bit about the geographic expansion opportunity? I think you did something like 55 or 60 outside of the U.S. last year. Can just talk about how that's now opened up? I have a follow-up as well after. Thanks.

Sure. Well, last year was obviously a little more complex in terms of marketing due to the fact that we really started marketing the system in Q1 of this year in the United States. But we've seen a substantial increase of placements in the United States, and I appreciate that, this is still a system in, I'd call a protective mode, and we're building critical mass of the system. We'll certainly provide then, clarity around some of the details. I would point to customer events like the AMP, but also others, where you'll see numerous posters and also use cases and also presentations on GeneReader showing the used case for the system. This is really a very customer-centric value proposition that is resonating extremely well with pathologists looking for benchtop sequencing systems.

The next question comes from line of Dan Arias of Citibank. Please go ahead.

Yeah, thanks for the questions. Roland, on the Instruments business, would you be willing to parse out growth there, excluding QIAsymphony contributions? And then maybe on TB, Peer, just wondering if you might want to touch on litigation and what you see as likely outcomes there? I know you don't get too detailed on the legal stuff, but it does look like the last round went to Oxford. So just wondering how you would see the likelihood of royalty injunction, et cetera, for those that are looking to handicap things there?

Yeah. Let me kick it off. I think on the Instrumentation side, it's quite obvious that GeneReader as well as QIAsymphony are actually have been very helpful in terms of instrumentation growth. I would say we have – on the softer part, it's around instrument service and few sample prep instruments, but mainly just – actually the service was softer this quarter.

Right. So, regarding litigation, as you know, Oxford filed a motion for preliminary injunction blocking upcoming launch of the fourth generation version of QuantiFERON-TB. This motion, as you know, was denied with – we have further trial dates set. But we're not really going to speculate where this goes. And I'd like to remind everybody, this is on a – this is around the patent that is expiring in 2019. And we clearly see that we have freedom to operate in this area. We understand, we are – it's a very important product for us and growing very rapidly, but this is something that we were – an area where we believe we have a clear freedom to operate going forward.

The next question comes from the line of Jack Meehan with Barclays. Please go ahead.

Thanks. So I wanted to continue the theme reflecting on last year's Investor Day. I had two questions for you on that. First, with QuantiFERON, great growth this year, but can you talk about the durability of the trajectory, still a sizable conversion opportunity, but is it tougher to find the wins? And then, just looking at the total company, you laid out a longer term target of 7% to 9% CER growth. What would it take to get in that range next year? Thanks.

Sure. I'll give – I'll ask Roland to give more details on that number range, but just simply removing, for instance, the slower growing HPV China franchise is definitely going to also provide us a benefit and in terms of the overall growth profile. And so we're very actively – proactively looking at our portfolio to maximize the growth opportunities and at the same time, ensure that we can follow through with the earnings per share targets that we have that are for a 12-plus range over that four year CAGR that we gave back then. The growth range that – for tuberculosis, the penetration is still at extremely low rates. We assume that the market, depending on how it is described, actually increased quite considerably over the last 18 months due to a number of markets opening up and we're seeing as you also saw in some of the announcements that even high prevalence countries are now routinely running large scale studies to consider latent TB as the appropriate test to be used versus active TB to contain the disease, it's scientifically, clinically – I think it's pretty clear that's the right thing to do, but it has to be further validated and that is happening. So, we're literally talking about a minimum of 55 million tests, skin tests being performed. And depending on what number people want to use today, it could be 75 million, it could be 80 million tests as a potential market opportunity, multiplied by the test price, and we're still at a very low penetration rate. So there is – there are several years to grow, many years to grow in this area until we reach saturations that would make it more difficult. And on top of that, we're also expanding actively the menu in this area, and I think we'll see more on that also in the year 2018.

Jack, and just to add on that, I think looking a little bit forward into 2018 and beyond, and again, also what we have seen this year so far, I think if you look at 2017 so far and also look at what we guided for for the first quarter, you can see that again, if we exclude the HPV franchise, which clearly has a certain volatility, as you know – some last two quarters, it was actually quite positive. So fourth quarter now will be again a little bit more negative again because it has a difficult period. And also addressing I think the China portfolio changes, as I said before, again, if you just look at both factors and exclude that on 2017, we would have every quarter – we do have actually in every quarter a 7%, 8% growth rate. So, I think we are moving in the right direction. We both know that HPV in U.S. again still creates some volatility, but clearly gets smaller in terms of size every quarter, and therefore, I think that is moving in the right direction as well. And the HPV stuff is rather something what we do because we believe there is more growth in it for QIAGEN mid-term so we rather want now bringing the portfolio in that direction and our distribution structure in that direction, but we also can even larger participate on that.

The next question comes from the line of Bill Quirk with Piper Jaffray. Please go ahead. William R. Quirk - Piper Jaffray & Co.: Great. Thanks. Good morning, everybody, or good afternoon rather. A couple of questions. First off, just on 4Q guidance, Roland, maybe you can help us think about this a little bit. I mean, you had a tough comp in the third quarter, we have a tough comp in the fourth quarter, the CER growth forecast is down a little. Is this having pretty much everything to do with the tender expiration? I guess that's the first question. And then secondly, just on U.S. TB growth, obviously, your competitor had some challenges with respect to some of the immigration policies. But just curious kind of where that business is growing in the states? And how are you thinking about the sustainable numbers in the U.S.? Appreciate your international comments a couple of questions ago. Thanks.

Let me start it. And I think just to be very clear on the fourth quarter again – and I think it's something what is again important to understand. Again, if you would do a co-acquisition, you clearly want us to add something to the guidance, but if you stop to produce products and sell the products that has an impact, it's worldwide. And again, we stopped a couple of million in terms of dollars, revenues, production – products for China, right, and that clearly is something what you have to consider as well, right? And so I would say, all-in that is the single biggest factor. TB, probably Peer can talk about that, but we have seen not only for the nine months period, north of 25% growth, but we also have seen it for the last three months. So, I think it is clearly a very strong success factor for us as well. Peer?

Yeah. So in terms of QuantiFERON, it's now several quarters in a row where we are gaining significant market share, not only against the skin test, but also against an already substantially smaller other commercial competitor. And, so I think it just shows the strong position we have in QuantiFERON, especially now augmented with the QuantiFERON-TB Gold Plus product. We are seeing growth in all segments. It's never easy to make a healthcare institution convert to a new technology and adopt that. It requires education. It requires also support in the transition process. But we have substantial resources on it, and also a great track record and the numbers speak for themselves. So we expect North America to continue to grow very well and especially also with the new opportunities outside the U.S., in particular also in Europe even, there's some exciting opportunities that are emerging that will allow us to continue growth for many years to come. But there is a lot more to happen in QuantiFERON and in TB, in general, at QIAGEN. And so we recognize the responsibility we have as a leader in this space, and I think you'll see some quite exciting things in this area coming from us over the course of 2018.

Yeah. And then Bill just a final word from my side. We actually added a new slide into the presentation, you might find it in the appendix on 23, where we actually guide you on the different layers of our guidance for the fourth quarter versus for the full year.

Your next question comes from the line of Gunnar Romer with Deutsche Bank. Please go ahead.

Gunnar Romer, Deutsche Bank. Thanks for taking my questions. The first one would be on outlook, again. Fully appreciate your decision to streamline the China operations, but nonetheless, I'm a bit surprised to see that for the fourth quarter, you are guiding organic growth ex-China from that slide down to 4% to 5% from 7% in the third quarter, despite what I believe is, in fact, a slightly softer comp. And, therefore, would kindly ask you to elaborate a bit further on this expectation and to what extent it includes an element of conservatism, if at all? And then, in this context as well, if you can put this fourth quarter guidance into perspective of the 7% to 9% growth target through to 2020 and whether the guide that slowed down in the fourth quarter points to a 2018 that maybe fall short of that corridor? And then, just a quick follow-up. On Japan, I've noticed a slight decline here in the third quarter. Curious, what's the – what has driven that and whether there's any structural that we should bear in mind? Thank you.

Roland, do you want to take the first two, and I take Japan? Okay.

Yeah, sure. I think Gunnar, I think as you said before, it's – what you said before is pointing to the right direction. Nevertheless again, just don't want to repeat myself, is we're clearly against starting to produce – selling – stopping – stop to sell products in China, because again, we have to free up capacity to implement other stuff. And just takes revenues out of the system at least for a quarter, I think that's very straight forward. Other thing, of course, which I think we are also pointing to in the call is, we clearly and you – and numbers are public as we release them every quarter, as well as we actually have very – much tougher comps in the fourth quarter as it comes to HPV test sales. U.S. HPV test sales actually had been for us 200 basis points in the fourth quarter. Again, if you normalize for that, you are back to the 8%, which we had in the first quarter, we had in the second quarter, which we had in the third quarter. And most likely, we will have between 7% and 8% in the fourth quarter. So all-in, I feel quite confident that nothing really has changed within QIAGEN and I also feel on track, if you look towards 2018, especially, again, and just to reemphasize as well, what we're doing in China is – it's because we do want to accelerate our business there. We see more opportunities. We do believe we just won a HPV partner, we have a larger footprint, we can reach more in an increasing market opportunity and we're grapping here more not only in absolute dollars, but also hopefully in absolute profitability and returns.

And, Gunnar, Japan, as you probably heard from many other companies in this area remains an extremely troubled market now for quite a few years. And we look at our growth rates there and they are typically below the average of the company. But what is quite remarkable is that all market research shows that we are gaining market share in these markets and the market is definitely a very important one for us going forward. We're also just able to add a new President of China after the retirement of the previous President, and so have been able to attract an excellent leader in this area that is working already to drive growth further. There is more opportunity in China even beyond the market share gains that we're currently recognizing.

The next question comes from the line of Derik de Bruin of Bank of America Merrill Lynch. Please go ahead.

Hi. Good morning, afternoon. A couple of questions. Just any sort of initial thoughts from some of your customers in the States on PAMA and just some of the regulatory changes there? Are you noticing any sort of hesitation in terms of spending as that – people sort of devaluate that? And also just on the regulatory front, we're also starting to see in China, some – starting to look at national tenders for certain medical devices. I'm just wondering how does that sort of look for your exposure in the diagnostics realm, is that something that could potentially come over in the future? Thanks.

Sure. Well, PAMA is clearly something that is creating confusion, immense confusion at the moment and the guidance that came out a few weeks ago and the increased clarity was definitely helpful even though still these many questions open. And so if you look at our portfolio, if you – for instance take, in the U.S., our big product, which is QuantiFERON, the majority of the sales are not reimbursed sales, but they are cost to the healthcare system to ensure a TB free work environment, i.e., healthcare workers screening. And so that takes a big chunk out of that. But obviously we do also sell a range of products that are and can be exposed to PAMA. What you might have noticed is that, there's – pathology was, to much lesser degree impacted by this and also some of the more high-end cancer testing areas, which is an area that we also have a strong area – approval area and there wasn't a reduction in the rates for HPV testing. But as we talked about before, that is 1.5% of our sales, so it's not going to push the needle too much. So while there's not really a huge flank of exposure out there, but I would like to say that the market is definitely, as you absolutely pointed out before, nervous and thinking this through, and looking at overall cost savings, especially for labs that are more impacted by it. I think there will be a strategic solution to all of this that some of you have already implied in your notes and that will provide further clarity on this going forward. But at the moment, until we really have this implemented and clarity around it, the confusion is the biggest enemy at the moment.

So with that, Peer and Roland, I'd like to end the call and thank all of you for your participation today. If you have any questions or follow-up, topics you'd like to address, please don't hesitate to give us a call. Thank you very much.

Thank you.

Ladies and gentlemen, this concludes today's conference call. Thank you for joining, and have a pleasant day. Good bye.